Hepatology International

Hepatology International is the peer-reviewed journal of the Asian Pacific Association for the Study of the Liver, published by Springer since 2007 and covering clinical and basic hepatology, with a 2025 Journal Impact Factor of 7.8《国际肝病》是（Asian Pacific Association for the Study of the Liver）的同行评审期刊，由（Springer）自 2007 年起出版，涵盖临床与基础肝病学，2025 年影响因子为 7.8。

Scope

• The journal covers adult and paediatric hepatobiliary disease and allied sciences该刊覆盖成人及儿童肝胆疾病与相关学科。
• Viral hepatitis, metabolic dysfunction-associated steatotic liver disease and alcohol-related liver disease are major topics病毒性肝炎、代谢功能障碍相关脂肪性肝病与酒精相关性肝病是主要议题。
• Hepatocellular carcinoma, liver transplantation and portal hypertension are regularly addressed肝细胞癌、肝移植与门静脉高压亦经常涉及。
• Contemporary basic science that illuminates clinical hepatology is published alongside clinical research该刊在发表临床研究的同时，也刊载有助于阐释临床肝病学的基础科学成果。
• New and emerging technologies, innovations and future trends in liver and biliary disorders are emphasised该刊重视肝脏与胆道疾病领域的新兴技术、创新与未来趋势。
• Consensus guidelines for diagnosis and treatment are a distinctive article type诊断与治疗共识指南是该刊颇具特色的文章类型。
• Original research, editorials, reviews, clinical cases and images, and video submissions are accepted, but case reports are not接受原创研究、社论、综述、临床病例与影像以及视频投稿，但不接受病例报告。

History

• The journal was founded in 2007 as the official publication of the Asian Pacific Association for the Study of the Liver该刊于 2007 年创办，作为（Asian Pacific Association for the Study of the Liver）的官方出版物。
• It is published by Springer under a hybrid model that combines subscription access with optional open access该刊由（Springer）以混合模式出版，兼有订阅访问与可选开放获取。
• Its Journal Impact Factor rose from 6.047 in 2021 and 9.029 in 2022 to 6.1 in 2024 and 7.8 in 2025, with a five-year value of 7.1其影响因子由 2021 年的 6.047 与 2022 年的 9.029，变为 2024 年的 6.1 与 2025 年的 7.8，五年影响因子为 7.1。
• The median time from submission to first decision is seven days, and the journal recorded 1.2 million downloads in 2025自投稿至首次决定的中间时间为 7 天，2025 年全文下载量达 120 万次。
• It is indexed in Science Citation Index Expanded, MEDLINE, Scopus and EMBASE该刊被（Science Citation Index Expanded）、（MEDLINE）、（Scopus）与（EMBASE）收录。
• Over half of the articles published in 2025 were linked to one or more of the United Nations Sustainable Development Goals2025 年发表的文章中有一半以上与联合国可持续发展目标中的一项或多项相关。

Editors

• The editors-in-chief are Masao Omata of the Yamanashi Prefectural Hospital Organization in Japan and Shiv Kumar Sarin of the Institute of Liver and Biliary Sciences in India主编为日本（Yamanashi Prefectural Hospital Organization）的（Masao Omata）与印度（Institute of Liver and Biliary Sciences）的（Shiv Kumar Sarin）。
• Associate editors include Jidong Jia of Beijing Friendship Hospital and Henry L. Y. Chan of the Chinese University of Hong Kong副编辑包括（Beijing Friendship Hospital）的（Jidong Jia）与（The Chinese University of Hong Kong）的（Henry L. Y. Chan）。
• Further associate editors are Jinlin Hou, Fusheng Wang, Manoj Kumar, Rakhi Maiwall, Dong Joon Kim and Han-Chieh Lin其他副编辑包括（Jinlin Hou）、（Fusheng Wang）、（Manoj Kumar）、（Rakhi Maiwall）、（Dong Joon Kim）与（Han-Chieh Lin）。
• A statistical editor and a group of assistant editors support the editorial office该刊设有统计编辑，并由一组助理编辑支持编辑部工作。
• The editorial board is drawn mainly from the Asia-Pacific region, with members also from Europe and North America编委会主要来自亚太地区，亦有欧洲与北美成员。
• Consensus documents are developed with APASL working groups, and the journal states explicitly that it does not accept case reports共识文件与（APASL）工作组共同制定，该刊明确表示不接受病例报告。